Roche Pharma China launches new R&D platform in Pudong
Swiss pharmaceutical company Roche is accelerating the construction of a new research and development (R&D) platform – the Roche Accelerator – in Pudong New Area, East China's Shanghai, which is expected to be completed by the end of this year, and will help transform scientific research achievements into technologies and products.
Biomedicine is among Shanghai's three leading industries, and one of Pudong's six core industries. In recent years, the area has released a slew of supportive measures to boost the growth of its biomedicine industry, and Roche, which has been stationed in Pudong's Zhangjiang, is now looking forward to contributing more to promoting the high-quality development of Pudong's biomedicine industry, according to Dr Shen Hong, head of Roche Innovation Center Shanghai.
Dr Shen said that the Roche Accelerator will make the most of the strong R&D strength of Roche to build a R&D and innovation platform with a global influence, in a bid to make breakthroughs in multiple fields, and promote the innovative development of China's biomedicine industry.
The new R&D platform has a total investment of nearly 300 million yuan ($44.97 million) and is expected to discover more first-in-class science and technologies, as well as help local innovators accelerate their drive to commercialize cutting-edge technologies, according to Dr Tang Qiusong, head of the Roche Accelerator.
The Roche Accelerator in Pudong New Area, East China's Shanghai is expected to be completed by the end of this year. [Photo/WeChat account: pdnews]